Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data
Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data
Jamie E. Chaft,1 Amy Cummings,2 Nisha Mohindra,3 Marcelo V. Negrao,4 Kai He,5 So Yeon Kim,6 Andreas Saltos,7 Tejas Patil,8 Elaine Shum,9 Philip Lammers,10 Katja Schulze,11 Qian Zhu,11 Mark T. Lin,11 Evelise Brandao,11 Celina Ngiam,11 Ilze Bara,11 Jay M. Lee2
KRAS G12C mutations are present in 12–14% of NSCLC cases and associated with poor prognosis1
Divarasib, a next-generation KRAS G12C inhibitor, showed a durable clinical benefit and manageable safety profile in patients with previously treated, advanced or metastatic KRAS G12C+ NSCLC2–4
In the phase III, Krascendo 1 study (NCT06497556) divarasib significantly improved PFS and OS compared with the approved KRAS G12C inhibitors sotorasib and adagrasib4
NAUTIKA1 (NCT04302025) is a phase II, umbrella study evaluating multiple neoadjuvant and adjuvant treatments for early-stage NSCLC with specific oncogenic drivers, including: KRAS G12C, ALK, ROS1, snd NTRK, as well as a PD-L1 selected cohort5
NAUTIKA1:Ⅱ-Ⅲ期驱动基因阳性可切除NSCLC的新辅助和辅助治疗伞式试验
|